Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77002 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL10457010 | 0.79 | EPHX2 (0.61) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL11650361 | 0.79 | EPHX2 (0.61) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL7980935 | 0.79 | NPC1 (0.59) | SMN1; SMN2EPHX1EPHX2MAPTNPC1 | |
| SCHEMBL6024478 | 0.78 | MAPT (0.55) | SMN1; SMN2TP53TSHRMAPTNPC1 | |
| SCHEMBL3175598 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL5681700 | 0.77 | F2 (0.42) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL5681693 | 0.76 | EPHX2 (0.56) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL8396654 | 0.76 | TP53 (0.56) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL5313666 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53EPHX1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| WO-2008100621-A2 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | claimed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| US-20040043403-A1 | Use of transcription or translation products of genes the expression levels of which correlate with the biological activity of an EGFR tyrosine kinase inhibitor | FURST PETER (CH) | 2004-03-04 | — | — | US | claimed |
| EP-1346062-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2003-09-24 | — | — | EP | claimed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | claimed |
| WO-2002050306-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-27 | — | — | WO | claimed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | claimed |
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | claimed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | claimed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1999023170-A1 | TRIPHENDIOXAZINE COLORANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-14 | — | — | WO | claimed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| US-5047570-A | Reacting nitrile with alkanol inpresence of hydrogen halide, then with malodinitrile | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | claimed |
| CN-110719907-B | Heterocyclic compound and composition containing same | 住友化学株式会社 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-4070337-A | Bichromophoric benzotriazole-styrene ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4062800-A | Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-3981884-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | SMN1; SMN2 1400/4885TP53 3031/4885EPHX1 2612/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | SMN1; SMN2 1689/4885TP53 3914/4885EPHX1 2441/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | SMN1; SMN2 1673/4885TP53 4212/4885EPHX1 2183/4885 |
| US-20040043403-A1 | Use of transcription or translation products of genes the expression levels of which correlate with the biological activity of an EGFR tyrosine kinase inhibitor | EGFR, ETF1, TCEA1 | SMN1; SMN2 4863/4885TP53 175/4885EPHX1 3554/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | SMN1; SMN2 1689/4885TP53 3914/4885EPHX1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.